SynthesisThe Cochrane database of systematic reviews2025

Phosphodiesterase type 5 inhibitor plus endothelin receptor antagonist compared to either alone for group 1 pulmonary arterial hypertension.

Yuji Oba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.